Interleukin-10 Genetically Modified Clinical-grade Mesenchymal Stromal Cells Markedly Reinforced Functional Recovery After Spinal Cord Injury Via Directing Alternative Activation of Macrophages

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2022 Mar 18

PMID 35300585

Authors

Tianyun Gao

Feifei Huang

Wenqing Wang

Yuanyuan Xie

Bin Wang

Affiliations

Soon will be listed here.

Abstract

Background: After spinal cord injury (SCI), dysregulated or nonresolving inflammatory processes can severely disturb neuronal homeostasis and drive neurodegeneration. Although mesenchymal stromal cell (MSC)-based therapies have showed certain therapeutic efficacy, no MSC therapy has reached its full clinical goal. In this study, we examine interleukin-10 (IL10) genetically modified clinical-grade MSCs (IL10-MSCs) and evaluate their clinical safety, effectiveness, and therapeutic mechanism in a completely transected SCI mouse model.

Methods: We established stable IL10-overexpressing human umbilical-cord-derived MSCs through electric transduction and screened out clinical-grade IL10-MSCs according to the criteria of cell-based therapeutic products, which were applied to mice with completely transected SCI by repeated tail intravenous injections. Then we comprehensively investigated the motor function, histological structure, and nerve regeneration in SCI mice, and further explored the potential therapeutic mechanism after IL10-MSC treatment.

Results: IL10-MSC treatment markedly reinforced locomotor improvement, accompanied with decreased lesion volume, regeneration of axons, and preservation of neurons, compared with naïve unmodified MSCs. Further, IL10-MSC transplantation increased the ratio of microglia to infiltrated alternatively activated macrophages (M2), and reduced the ratio of classically activated macrophages (M1) at the injured spinal cord, meanwhile increasing the percentage of Treg and Th2 cells, and reducing the percentage of Th1 cells in the peripheral circulatory system. In addition, IL10-MSC administration could prevent apoptosis and promote neuron differentiation of neural stem cells (NSCs) under inflammatory conditions in vitro.

Conclusions: IL10-MSCs exhibited a reliable safety profile and demonstrated promising therapeutic efficacy in SCI compared with naïve MSCs, providing solid support for future clinical application of genetically engineered MSCs.

Citing Articles

Advances in 3D printing combined with tissue engineering for nerve regeneration and repair.

Liao W, Shi Y, Li Z, Yin X J Nanobiotechnology. 2025; 23(1):5.

PMID: 39754257 PMC: 11697815. DOI: 10.1186/s12951-024-03052-9.

Regulation of dynamic spatiotemporal inflammation by nanomaterials in spinal cord injury.

Liu Z, Xiang C, Zhao X, Aizawa T, Niu R, Zhao J J Nanobiotechnology. 2024; 22(1):767.

PMID: 39696584 PMC: 11657436. DOI: 10.1186/s12951-024-03037-8.

IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity.

Tai T, Hsu D, Yang Y, Tsai C, Shi J, Wu C Br J Cancer. 2024; 132(1):126-136.

PMID: 39592739 PMC: 11723913. DOI: 10.1038/s41416-024-02893-3.

Single-cell RNA sequencing integrated with bulk RNA sequencing analysis reveals the protective effects of lactate-mediated lactylation of microglia-related proteins on spinal cord injury.

Zhang B, Li F, Shi Y, Ji C, Kong Q, Sun K CNS Neurosci Ther. 2024; 30(9):e70028.

PMID: 39218784 PMC: 11366449. DOI: 10.1111/cns.70028.

The Role of Interleukin-10 in the Pathogenesis and Treatment of a Spinal Cord Injury.

Patilas C, Varsamos I, Galanis A, Vavourakis M, Zachariou D, Marougklianis V Diagnostics (Basel). 2024; 14(2).

PMID: 38248028 PMC: 10814517. DOI: 10.3390/diagnostics14020151.

References

Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J . MSC-secreted TGF-β regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther. 2019; 10(1):345. PMC: 6878630. DOI: 10.1186/s13287-019-1447-y. View

Geissmann F, Manz M, Jung S, Sieweke M, Merad M, Ley K . Development of monocytes, macrophages, and dendritic cells. Science. 2010; 327(5966):656-61. PMC: 2887389. DOI: 10.1126/science.1178331. View

Zhou X, Wahane S, Friedl M, Kluge M, Friedel C, Avrampou K . Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B2. Nat Neurosci. 2020; 23(3):337-350. PMC: 7412870. DOI: 10.1038/s41593-020-0597-7. View

Oh S, Choi K, Yoo J, Kim D, Kim S, Jeon S . A Phase III Clinical Trial Showing Limited Efficacy of Autologous Mesenchymal Stem Cell Therapy for Spinal Cord Injury. Neurosurgery. 2016; 78(3):436-47. DOI: 10.1227/NEU.0000000000001056. View

Aziz I, Che Ramli M, Mohd Zain N, Sanusi J . Behavioral and Histopathological Study of Changes in Spinal Cord Injured Rats Supplemented with Spirulina platensis. Evid Based Complement Alternat Med. 2014; 2014:871657. PMC: 4135169. DOI: 10.1155/2014/871657. View

Orihuela R, McPherson C, Harry G . Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2015; 173(4):649-65. PMC: 4742299. DOI: 10.1111/bph.13139. View

Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F . Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008; 15(10):730-8. DOI: 10.1038/gt.2008.39. View

Chio J, Wang J, Badner A, Hong J, Surendran V, Fehlings M . The effects of human immunoglobulin G on enhancing tissue protection and neurobehavioral recovery after traumatic cervical spinal cord injury are mediated through the neurovascular unit. J Neuroinflammation. 2019; 16(1):141. PMC: 6615094. DOI: 10.1186/s12974-019-1518-0. View

Smith D, Dumont C, Park J, Ciciriello A, Guo A, Tatineni R . Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model. Tissue Eng Part A. 2020; 26(11-12):672-682. PMC: 7310216. DOI: 10.1089/ten.TEA.2019.0321. View

10.

Kigerl K, Gensel J, Ankeny D, Alexander J, Donnelly D, Popovich P . Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009; 29(43):13435-44. PMC: 2788152. DOI: 10.1523/JNEUROSCI.3257-09.2009. View

11.

Zhou Z, Peng X, Insolera R, Fink D, Mata M . Interleukin-10 provides direct trophic support to neurons. J Neurochem. 2009; 110(5):1617-27. PMC: 2737090. DOI: 10.1111/j.1471-4159.2009.06263.x. View

12.

Zhou Z, Peng X, Insolera R, Fink D, Mata M . IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol. 2009; 220(1):183-90. PMC: 2788918. DOI: 10.1016/j.expneurol.2009.08.018. View

13.

Moll G, Ankrum J, Kamhieh-Milz J, Bieback K, Ringden O, Volk H . Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol Med. 2019; 25(2):149-163. DOI: 10.1016/j.molmed.2018.12.006. View

14.

Li J, Liu Y, Xu H, Fu Q . Nanoparticle-Delivered IRF5 siRNA Facilitates M1 to M2 Transition, Reduces Demyelination and Neurofilament Loss, and Promotes Functional Recovery After Spinal Cord Injury in Mice. Inflammation. 2016; 39(5):1704-17. DOI: 10.1007/s10753-016-0405-4. View

15.

Silva N, Sousa N, Reis R, Salgado A . From basics to clinical: a comprehensive review on spinal cord injury. Prog Neurobiol. 2013; 114:25-57. DOI: 10.1016/j.pneurobio.2013.11.002. View

16.

Phetfong J, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasittikul V . Osteoporosis: the current status of mesenchymal stem cell-based therapy. Cell Mol Biol Lett. 2017; 21:12. PMC: 5414670. DOI: 10.1186/s11658-016-0013-1. View

17.

Zhang B, Bailey W, Braun K, Gensel J . Age decreases macrophage IL-10 expression: Implications for functional recovery and tissue repair in spinal cord injury. Exp Neurol. 2015; 273:83-91. PMC: 4644435. DOI: 10.1016/j.expneurol.2015.08.001. View

18.

He X, Yu H, Lin S, Li Y . Advances in the application of mesenchymal stem cells, exosomes, biomimetic materials, and 3D printing in osteoporosis treatment. Cell Mol Biol Lett. 2021; 26(1):47. PMC: 8591870. DOI: 10.1186/s11658-021-00291-8. View

19.

Shemer A, Scheyltjens I, Frumer G, Kim J, Grozovski J, Ayanaw S . Interleukin-10 Prevents Pathological Microglia Hyperactivation following Peripheral Endotoxin Challenge. Immunity. 2020; 53(5):1033-1049.e7. DOI: 10.1016/j.immuni.2020.09.018. View

20.

Popovich P, Guan Z, McGaughy V, Fisher L, Hickey W, Basso D . The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J Neuropathol Exp Neurol. 2002; 61(7):623-33. DOI: 10.1093/jnen/61.7.623. View